Zentalis Pharmaceuticals, Inc. Payments to Acquire Debt Securities, Available-for-sale
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Payments to Acquire Debt Securities, Available-for-sale of $59.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $29.98M, a 25.41% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $29.95M, a 53.36% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $30.24M, a 22.90% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $49.53M, a 16.38% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $139.49M, a 9.01% increase from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $127.96M, a 76.70% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $549.18M, a 3.00% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $533.16M, a 46.67% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $59.93M 10-Q · filed 2026-08-06 | $90.17M derived: sum of 3 quarters · filed 2026-08-06 | $139.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $29.95M 10-Q · filed 2026-05-12 | $60.19M derived: sum of 2 quarters · filed 2026-05-12 | $109.72M derived: sum of 3 quarters · filed 2026-05-12 | $149.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $30.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $79.77M derived: sum of 2 quarters · filed 2026-03-26 | $119.96M derived: sum of 3 quarters · filed 2026-08-06 | $139.49M 10-K · filed 2026-03-26 |
| 2025-09-30 | $49.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $89.72M derived: sum of 2 quarters · filed 2026-08-06 | $109.25M 10-Q · filed 2025-11-10 | $148.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $40.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $59.72M 10-Q · filed 2026-08-06 | $98.93M derived: sum of 3 quarters · filed 2026-08-06 | $158.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $19.53M 10-Q · filed 2026-05-12 | $58.75M derived: sum of 2 quarters · filed 2026-05-12 | $117.98M derived: sum of 3 quarters · filed 2026-05-12 | $137.38M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $39.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $98.45M derived: sum of 2 quarters · filed 2026-03-26 | $117.85M derived: sum of 3 quarters · filed 2026-03-26 | $127.96M 10-K · filed 2026-03-26 |
| 2024-09-30 | $59.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $78.63M derived: sum of 2 quarters · filed 2025-11-10 | $88.75M 10-Q · filed 2025-11-10 | $184.73M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $19.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $29.51M 10-Q · filed 2025-08-06 | $125.50M derived: sum of 3 quarters · filed 2026-03-26 | $389.61M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $10.12M 10-Q · filed 2025-05-14 | $106.10M derived: sum of 2 quarters · filed 2026-03-26 | $370.21M derived: sum of 3 quarters · filed 2026-03-26 | $495.42M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $95.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $360.10M derived: sum of 2 quarters · filed 2026-03-26 | $485.30M derived: sum of 3 quarters · filed 2026-03-26 | $549.18M 10-K · filed 2026-03-26 |
| 2023-09-30 | $264.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $389.32M derived: sum of 2 quarters · filed 2024-11-12 | $453.19M 10-Q · filed 2024-11-12 | $579.18M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $125.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $189.09M 10-Q · filed 2024-08-09 | $315.07M derived: sum of 3 quarters · filed 2025-03-26 | $444.67M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $63.88M 10-Q · filed 2024-05-07 | $189.86M derived: sum of 2 quarters · filed 2025-03-26 | $319.46M derived: sum of 3 quarters · filed 2025-03-26 | $517.79M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $125.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $255.59M derived: sum of 2 quarters · filed 2025-03-26 | $453.91M derived: sum of 3 quarters · filed 2025-03-26 | $533.16M 10-K · filed 2025-03-26 |
| 2022-09-30 | $129.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $327.92M derived: sum of 2 quarters · filed 2023-11-06 | $407.18M 10-Q · filed 2023-11-06 | $490.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $198.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $277.58M 10-Q · filed 2023-08-09 | $360.80M derived: sum of 3 quarters · filed 2024-02-27 | $563.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $79.25M 10-Q · filed 2023-05-10 | $162.48M derived: sum of 2 quarters · filed 2024-02-27 | $364.95M derived: sum of 3 quarters · filed 2024-02-27 | $388.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $83.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $285.70M derived: sum of 2 quarters · filed 2024-02-27 | $309.07M derived: sum of 3 quarters · filed 2024-02-27 | $363.51M 10-K · filed 2024-02-27 |
| 2021-09-30 | $202.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $225.85M derived: sum of 2 quarters · filed 2022-11-09 | $280.29M 10-Q · filed 2022-11-09 | $377.18M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $23.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $77.81M 10-Q · filed 2022-08-09 | $174.71M derived: sum of 3 quarters · filed 2023-03-01 | $341.56M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $54.43M 10-Q · filed 2022-05-05 | $151.33M derived: sum of 2 quarters · filed 2023-03-01 | $318.18M derived: sum of 3 quarters · filed 2023-03-01 | $455.42M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $96.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $263.75M derived: sum of 2 quarters · filed 2023-03-01 | $400.98M derived: sum of 3 quarters · filed 2023-03-01 | $400.98M 10-K · filed 2023-03-01 |
| 2020-09-30 | $166.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $304.08M derived: sum of 2 quarters · filed 2021-11-10 | $304.08M 10-Q · filed 2021-11-10 | $304.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $137.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $137.24M 10-Q · filed 2021-08-12 | $137.24M derived: sum of 3 quarters · filed 2022-02-24 | $137.24M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |